National Cancer Institute; Notice of Meeting, 60132 [2010-24413]
Download as PDF
60132
Federal Register / Vol. 75, No. 188 / Wednesday, September 29, 2010 / Notices
Dated: September 22, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Scientific Management Review Board.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
erowe on DSK5CLS3C1PROD with NOTICES
Name of Committee: Office of AIDS
Research Advisory Council.
Date: November 9, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: The theme of the meeting will be
‘‘HIV/AIDS and Adolescents.’’ The meeting
will focus on research to address: The
epidemiology of HIV infection among
adolescents; HIV prevention, treatment and
care for adolescents; biological and cognitive
development of HIV-infected adolescents;
and ethical and regulatory issues for
involving youth in AIDS clinical research.
An update also will be provided on the
OARAC Working Groups for HIV Treatment
and Prevention Guidelines.
Place: National Institutes of Health, 5635
Fishers Lane, Terrace Level, Rockville, MD
20852.
Contact Person: Robert Eisinger, PhD,
Executive Secretary, Director Of Scientific
And Program Operations, Therapeutics
Coordinating Committee, Office of AIDS
Research, 5635 Fishers Lane, Msc 9310, Suite
400, Rockville, MD 20852, (301) 496–0357,
be4y@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.oar.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
VerDate Mar<15>2010
15:17 Sep 28, 2010
Jkt 220001
[FR Doc. 2010–24405 Filed 9–28–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Director’s
Consumer Liaison Group.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Director’s Consumer Liaison Group.
Date: October 14–16, 2010.
Time: 11 a.m. to 12 p.m.
Agenda: Director’s Update; Emerging
Opportunities in Gen and Target-Based
Research in the NCI Intramural Program;
Expert Panel and Board Discussion on the
Implications of Gene and Target-Based
Research Approaches in the Research
Paradigm.
Place: National Institutes of Health,
Building 60, 1 Cloister Court, Room 142,
Bethesda, MD 20814.
Contact Person: Benjamin Carollo, MPA,
Advocacy Relations Manager, Office of
Advocacy Relations, Building 31, Room
10A30, 31 Center Drive, MSC 2580, National
Cancer Institute, NIH, DHHS, Bethesda, MD
20892–2580, 301–496–0307,
carollob@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/dclg/dclg.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: September 22, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–24413 Filed 9–28–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2) notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Experimental Therapeutics Program (NExT).
Date: October 7, 2010.
Time: 8:30 a.m.–4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Dr. Barbara Mroczkowski,
Executive Secretary, NCI Experimental
Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room 3A44,
E:\FR\FM\29SEN1.SGM
29SEN1
Agencies
[Federal Register Volume 75, Number 188 (Wednesday, September 29, 2010)]
[Notices]
[Page 60132]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-24413]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Cancer Institute Director's Consumer Liaison Group.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: National Cancer Institute Director's Consumer
Liaison Group.
Date: October 14-16, 2010.
Time: 11 a.m. to 12 p.m.
Agenda: Director's Update; Emerging Opportunities in Gen and
Target-Based Research in the NCI Intramural Program; Expert Panel
and Board Discussion on the Implications of Gene and Target-Based
Research Approaches in the Research Paradigm.
Place: National Institutes of Health, Building 60, 1 Cloister
Court, Room 142, Bethesda, MD 20814.
Contact Person: Benjamin Carollo, MPA, Advocacy Relations
Manager, Office of Advocacy Relations, Building 31, Room 10A30, 31
Center Drive, MSC 2580, National Cancer Institute, NIH, DHHS,
Bethesda, MD 20892-2580, 301-496-0307, carollob@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: deainfo.nci.nih.gov/advisory/dclg/dclg.htm, where an agenda
and any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: September 22, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-24413 Filed 9-28-10; 8:45 am]
BILLING CODE 4140-01-P